Context Therapeutics(CNTX)
$0.22+0.03 (+15.51%)
CNTX
Context Therapeutics financials statements
$0.22
At close:+0.03 (+15.51%)
Want to see CNTX full AI Analyst Report?
Context Therapeutics (CNTX) Ratios
329 Followers
Context Therapeutics Ratios
CNTX's free cash flow for Q2 2026 was $-7.04M. For the 2026 fiscal year, CNTX's free cash flow was decreased by $-18.49K and operating cash flow was $-7.02M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.52 | 35.62 | 3.83 | 11.80 | 16.90 |
| Quick Ratio | 8.52 | 35.62 | 3.83 | 11.80 | 16.90 |
| Cash Ratio | 8.23 | 34.36 | 3.45 | 11.07 | 16.36 |
| Solvency Ratio | -4.50 | -9.34 | -5.71 | -4.62 | -3.45 |
| Operating Cash Flow Ratio | -3.29 | -5.30 | -5.02 | -4.22 | -2.90 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 60.33M | $ 95.04M | $ 11.86M | $ 34.65M | $ 48.22M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.13 | 1.03 | 1.35 | 1.09 | 1.06 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | -27.17 | -161.78 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | -28.11 | -163.85 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.00 | 0.00 | 0.00 | 0.04 | 0.02 |
| Net Debt to EBITDA | 1.82 | 3.53 | 0.58 | 2.38 | 4.78 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 90.99% | 89.31% | 95.58% | 96.45% | 99.34% |
| Return on Assets (ROA) | -52.74% | -27.24% | -149.19% | -39.08% | -20.38% |
| Return on Equity (ROE) | -59.73% | -28.05% | -201.87% | -42.68% | -21.66% |
| Return on Capital Employed (ROCE) | -65.65% | -31.37% | -211.21% | -44.25% | -21.81% |
| Return on Invested Capital (ROIC) | -65.53% | -31.34% | -211.21% | -44.18% | -21.81% |
| Return on Tangible Assets | -52.74% | -27.24% | -149.19% | -39.08% | -20.38% |
| Earnings Yield | -25.82% | -43.57% | -132.83% | -142.58% | -138.71% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.28 | -0.25 | -1.32 | -0.85 | -3.10 |
| Free Cash Flow Per Share | -0.28 | -0.50 | -1.32 | -0.88 | -3.19 |
| Dividend Paid and CapEx Coverage Ratio | -777.23 | -0.99 | 0.00 | -25.24 | -35.20 |
| Capital Expenditure Coverage Ratio | -777.23 | -0.99 | 0.00 | -25.24 | -35.20 |
| Operating Cash Flow Coverage Ratio | -235.45 | -66.35 | 0.00 | -246.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -18.88% | -47.79% | -116.66% | -135.38% | -120.04% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.87 | -2.30 | -0.75 | -0.70 | -0.72 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 2.31 | 0.64 | 1.52 | 0.30 | 0.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.30 | -2.09 | -0.86 | -0.74 | -0.83 |
| Price-to-Operating Cash Flow Ratio | -5.30 | -4.21 | -0.86 | -0.77 | -0.86 |
| Price-to-Earnings Growth (PEG) Ratio | 0.22 | 0.03 | -0.01 | 0.01 | 0.00 |
| Enterprise Value Multiple | -2.05 | 1.23 | -0.14 | 1.68 | 4.05 |
| Enterprise Value | 74.04M | -32.87M | 3.59M | -25.04M | -42.10M |
| EV to EBITDA | -2.05 | 1.23 | -0.14 | 1.68 | 4.05 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -2.80 | 1.12 | -0.17 | 1.78 | 4.65 |
| EV to Operating Cash Flow | -2.81 | 2.26 | -0.17 | 1.85 | 4.78 |
| Tangible Book Value Per Share | 0.64 | 1.63 | 0.74 | 2.18 | 17.03 |
| Shareholders’ Equity Per Share | 0.64 | 1.63 | 0.74 | 2.18 | 17.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.38 | -0.46 | -1.50 | -0.93 | -3.69 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.00 | 0.96 | 1.00 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.73 | 0.54 | 0.88 | 0.91 | 0.84 |
Currency in USD
